Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer

Roche today announced results from the global phase III ALUR study showing that Alecensa ® significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by 85% compared to chemotherapy in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), who had progressed following treatment with platinum-based chemothe rapy and crizotinib (hazard ratio [HR]=0.15, 95% CI: 0.08-0.29, p
Source: Roche Media News - Category: Pharmaceuticals Source Type: news